scholarly journals Novel Strategies for Nanoparticle-Based Radiosensitization in Glioblastoma

2021 ◽  
Vol 22 (18) ◽  
pp. 9673
Author(s):  
Henry Ruiz-Garcia ◽  
Cristopher Ramirez-Loera ◽  
Timothy D. Malouff ◽  
Danushka S. Seneviratne ◽  
Joshua D. Palmer ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Treatment Failure ◽  
Treatment Response ◽  
Current Treatment ◽  
Therapeutic Strategies ◽  
Current Evidence ◽  
Preoperative Radiation ◽  
Treatment Paradigm ◽  
Antitumor Properties

Radiotherapy (RT) is one of the cornerstones in the current treatment paradigm for glioblastoma (GBM). However, little has changed in the management of GBM since the establishment of the current protocol in 2005, and the prognosis remains grim. Radioresistance is one of the hallmarks for treatment failure, and different therapeutic strategies are aimed at overcoming it. Among these strategies, nanomedicine has advantages over conventional tumor therapeutics, including improvements in drug delivery and enhanced antitumor properties. Radiosensitizing strategies using nanoparticles (NP) are actively under study and hold promise to improve the treatment response. We aim to describe the basis of nanomedicine for GBM treatment, current evidence in radiosensitization efforts using nanoparticles, and novel strategies, such as preoperative radiation, that could be synergized with nanoradiosensitizers.

scholarly journals The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies

2016 ◽  
Vol 8 (3) ◽  
pp. 99-105 ◽  
Author(s):  
Alan P. Skarbnik ◽  
Stefan Faderl
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Standard Of Care ◽  
Current Treatment ◽  
Lymphocytic Leukemia ◽  
Current Evidence ◽  
Treatment Paradigm

Chemoimmunotherapy (CIT) has become a cornerstone in the treatment of patients with chronic lymphocytic leukemia (CLL). The combination of fludarabine, cyclophosphamide and rituximab (FCR) has emerged as the standard of care for therapy of previously untreated patients with CLL who are younger than 65 years and have no significant comorbidities. In this article, we review the role of FCR in the current treatment paradigm for CLL.

Natural, Synthetic and their Combinatorial Nanocarriers Based Drug Delivery System in the Treatment Paradigm for Wound Healing Via Dermal Targeting

2020 ◽  
Vol 26 (36) ◽  
pp. 4551-4568
Author(s):  
Mohammad Kashif Iqubal ◽  
Sadaf Saleem ◽  
Ashif Iqubal ◽  
Aiswarya Chaudhuri ◽  
Faheem Hyder Pottoo ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Wound Healing ◽  
Photodynamic Therapy ◽  
Growth Factors ◽  
Combination Therapy ◽  
Healing Process ◽  
Wound Healing Process ◽  
Wound Site ◽  
Synthetic Drugs ◽  
Treatment Paradigm

A wound refers to the epithelial loss, accompanied by loss of muscle fibers collagen, nerves and bone instigated by surgery, trauma, frictions or by heat. Process of wound healing is a compounded activity of recovering the functional integrity of the damaged tissues. This process is mediated by various cytokines and growth factors usually liberated at the wound site. A plethora of herbal and synthetic drugs, as well as photodynamic therapy, is available to facilitate the process of wound healing. Generally, the systems used for the management of wounds tend to act through covering the ruptured site, reduce pain, inflammation, and prevent the invasion and growth of microorganisms. The available systems are, though, enough to meet these requirements, but the involvement of nanotechnology can ameliorate the performance of these protective coverings. In recent years, nano-based formulations have gained immense popularity among researchers for the wound healing process due to the enhanced benefits they offer over the conventional preparations. Hereupon, this review aims to cover the entire roadmap of wound healing, beginning from the molecular factors involved in the process, the various synthetic and herbal agents, and combination therapy available for the treatment and the current nano-based systems available for delivery through the topical route for wound healing.

Nano Drug Delivery in Treatment of Oral Cancer, A Review of the Literature

2019 ◽  
Vol 20 (10) ◽  
pp. 1008-1017 ◽  
Author(s):  
Vandita Kakkar ◽  
Manoj Kumar Verma ◽  
Komal Saini ◽  
Indu Pal Kaur
Keyword(s):  
Drug Delivery ◽  
Oral Cancer ◽  
Treatment Options ◽  
Oral Submucous Fibrosis ◽  
Survival Rates ◽  
Cancer Therapeutics ◽  
Developed Countries ◽  
Current Treatment ◽  
Poor Overall Survival ◽  
Hereditary Disorders

Oral Cancer (OC) is a serious and growing problem which constitutes a huge burden on people in more and less economically developed countries alike. The scenario is clearly depicted from the increase in the expected number of new cases in the US diagnosed with OC from 49,670 people in 2016, to 49,750 cases in 2017. The situation is even more alarming in India, with 75,000 to 80,000 new cases being reported every year, thus making it the OC capital of the world. Leukoplakia, erythroplakia, oral lichen planus, oral submucous fibrosis, discoid lupus erythmatosus, hereditary disorders such as dyskeratosis congenital and epidermolisys bullosa are highlighted by WHO expert working group as the predisposing factors increasing the risk of OC. Consumption of tobacco and alcohol, genetic factors, and human papilloma virus are assigned as the factors contributing to the aetiology of OC. On the other hand, pathogenesis of OC involves not only apoptosis but also pain, inflammation and oxidative stress. Inspite of current treatment options (surgery, radiotherapy, and chemotherapy), OC is often associated with recurrence and formation of secondary primary tumours resulting in poor overall survival rates (∼50%). The intervention of nano technology-based drug delivery systems as therapeutics for cancers is often viewed as a cutting edge for technologists. Though ample literature on the usefulness of nano-coutured cancer therapeutics, rarely any product is in pipeline. Yet, despite all the hype about nanotechnology, there are few ongoing trials. This review discusses the current and future trends of nano-based drug delivery for the treatment of OC.

scholarly journals COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies

2021 ◽  
Author(s):  
Vrishali S. Salian ◽  
Jessica A. Wright ◽  
Peter T. Vedell ◽  
Sanjana Nair ◽  
Chenxu Li ◽  
...  
Keyword(s):  
Current Treatment ◽  
Therapeutic Strategies

Effects of Fasting on Chemotherapy Treatment Response: A Systematic Review of Current Evidence and Suggestions for the Design of Future Clinical Trials

2021 ◽  
pp. 1-9
Author(s):  
Esther Heyde Selke Costa ◽  
Jenifer Faria Krüger ◽  
Carolina Q. Camargo ◽  
Vinícius Basso Preti ◽  
Elaine Hillesheim ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Treatment Response ◽  
Current Evidence ◽  
Chemotherapy Treatment

scholarly journals Stereotactic Laser Interstitial Thermal Therapy for Recurrent High-Grade Gliomas

Neurosurgery ◽  
2016 ◽  
Vol 79 (suppl_1) ◽  
pp. S24-S34 ◽  
Author(s):  
Ian Lee ◽  
Steven Kalkanis ◽  
Constantinos G. Hadjipanayis
Keyword(s):  
Thermal Therapy ◽  
Neurological Deficits ◽  
Current Evidence ◽  
High Grade ◽  
Medline Search ◽  
Laser Interstitial Thermal Therapy ◽  
Ablation Volume ◽  
Treatment Paradigm ◽  
High Grade Gliomas

Abstract BACKGROUND: The value of maximal safe cytoreductive surgery in recurrent high-grade gliomas (HGGs) is gaining wider acceptance. However, patients may harbor recurrent tumors that may be difficult to access with open surgery. Laser interstitial thermal therapy (LITT) is emerging as a technique for treating a variety of brain pathologies, including primary and metastatic tumors, radiation necrosis, and epilepsy. OBJECTIVE: To review the role of LITT in the treatment of recurrent HGGs, for which current treatments have limited efficacy, and to discuss the possible role of LITT in the disruption of the blood-brain barrier to increase delivery of chemotherapy locoregionally. METHODS: A MEDLINE search was performed to identify 17 articles potentially appropriate for review. Of these 17, 6 reported currently commercially available systems and as well as magnetic resonance thermometry to monitor the ablation and, thus, were thought to be most appropriate for this review. These studies were then reviewed for complications associated with LITT. Ablation volume, tumor coverage, and treatment times were also reviewed. RESULTS: Sixty-four lesions in 63 patients with recurrent HGGs were treated with LITT. Frontal (n = 34), temporal (n = 14), and parietal (n = 16) were the most common locations. Permanent neurological deficits were seen in 7 patients (12%), vascular injuries occurred in 2 patients (3%), and wound infection was observed in 1 patient (2%). Ablation coverage of the lesions ranged from 78% to 100%. CONCLUSION: Although experience using LITT for recurrent HGGs is growing, current evidence is insufficient to offer a recommendation about its role in the treatment paradigm for recurrent HGGs.

scholarly journals Complementary role of mathematical modeling in preclinical glioblastoma: differentiating poor drug delivery from drug insensitivity

2021 ◽  
Author(s):  
Javier C. Urcuyo ◽  
Susan Christine Massey ◽  
Andrea Hawkins-Daarud ◽  
Bianca-Maria Marin ◽  
Danielle M. Burgenske ◽  
...  
Keyword(s):  
Mathematical Modeling ◽  
Drug Delivery ◽  
Clinical Trials ◽  
Treatment Response ◽  
Blood Brain Barrier ◽  
Brain Barrier ◽  
Significant Heterogeneity ◽  
Current Standard ◽  
Modeling Approach ◽  
Blood Brain

AbstractGlioblastoma is the most malignant primary brain tumor with significant heterogeneity and a limited number of effective therapeutic options. Many investigational targeted therapies have failed in clinical trials, but it remains unclear if this results from insensitivity to therapy or poor drug delivery across the blood-brain barrier. Using well-established EGFR-amplified patient-derived xenograft (PDX) cell lines, we investigated this question using an EGFR-directed therapy. With only bioluminescence imaging, we used a mathematical model to quantify the heterogeneous treatment response across the three PDX lines (GBM6, GBM12, GBM39). Our model estimated the primary cause of intracranial treatment response for each of the lines, and these findings were validated with parallel experimental efforts. This mathematical modeling approach can be used as a useful complementary tool that can be widely applied to many more PDX lines. This has the potential to further inform experimental efforts and reduce the cost and time necessary to make experimental conclusions.Author summaryGlioblastoma is a deadly brain cancer that is difficult to treat. New therapies often fail to surpass the current standard of care during clinical trials. This can be attributed to both the vast heterogeneity of the disease and the blood-brain barrier, which may or may not be disrupted in various regions of tumors. Thus, while some cancer cells may develop insensitivity in the presence of a drug due to heterogeneity, other tumor areas are simply not exposed to the drug. Being able to understand to what extent each of these is driving clinical trial results in individuals may be key to advancing novel therapies. To address this challenge, we used mathematical modeling to study the differences between three patient-derived tumors in mice. With our unique approach, we identified the reason for treatment failure in each patient tumor. These results were validated through rigorous and time-consuming experiments, but our mathematical modeling approach allows for a cheaper, quicker, and widely applicable way to come to similar conclusions.

Sign in / Sign up

Export Citation Format

Share Document